Tumor necrosis factors blocking agents: Analogies and differences

Acta Biomedica

Volumn 83, Issue 1, 2012, Pages 72-80

  Benucci, Maurizio ^a   Saviola, Gianantonio ^b   Manfredi, Mariangela ^c   Sarzi Puttini, Piercarlo ^d   Atzeni, Fabiola ^d  

^a Hospital di S Giovanni di Dio   (Italy)

^b IRCCS   (Italy)

^c Hospital S Giovanni di Dio   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Anti TNF agents; Pharmacokinetic; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN ANTIBODY COMPLEX; APOPTOSIS; ARTICLE; BINDING AFFINITY; CELL ACTIVITY; CELL DEATH; COMPLEMENT DEPENDENT CYTOTOXICITY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; GENE EXPRESSION; RHEUMATOID ARTHRITIS;

ANIMALS; ANTIGEN-ANTIBODY COMPLEX; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84864258538     PISSN: 03924203     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Carswell EA, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975; 72: 3666-70.
2. Elliott MJ, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993; 36: 1681-90. (Pubitemid 23360007)
3. Kriegler M, Perez C, DeFay K, Albert I, Lu SD. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 1988; 53: 45-53.
4. Luettiq B, Decker T, Lohmann-Matthes ML. Evidence for the existence of two forms of membrane tumor necrosis factor: an integral protein and a molecule attached to its receptor. J Immunol 1989; 143: 4034-8. (Pubitemid 20012591)
5. Bazzoni F, Beutler B.The tumor necrosis factor ligand and receptor families. N Engl J Med 1996; 334:1717-25. (Pubitemid 26193625)
6. Moss ML, Jin SL, Milla ME, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumournecrosis factor-alpha. Nature 1997; 385: 733-6. (Pubitemid 27098095)
7. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997; 385: 729-33. (Pubitemid 27098094)
8. Vandenabeele P, Declercq W, Beyaert R, Fiers W.Two tumour necrosis factor receptors: structure and function. Trends Cell Biol 1995; 5: 392-9.
9. Tang P, Hung M-C, Klostergaard J. Human pro-tumor necrosis factor is a homotrimer. Biochemistry 1996; 35: 8216-25. (Pubitemid 26234923)
10. Eissner G, Kolch W, Scheurich P. Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev 2004; 15: 353-66. (Pubitemid 39140699)
11. Harashima S, Horiuchi T, Hatta N, et al. Outside-to-inside signal through the membrane TNF-CX induces E-selectin (CD62E) expression on activated human CD4+ T c&s. J Immunol 2001; 166: 130-6. (Pubitemid 32038425)
12. Vudattu NK, Holler E, Ewing P, et al. Reverse signalling of membrane-integrated tumour necrosis factor differentially regulated alloresponses of CD4+ and CD8+ T cells against human mirovascular endothelial cells. Immunology 2005;115:536-43. (Pubitemid 41032441)
13. Eissner G, Kirchner S, Lindner H, et al. Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages. J Immunol 2000; 164: 6193-8. (Pubitemid 30408797)
14. Xin L, Wang J , Zhang H, et al. Dual regulation of soluble tumor necrosis factor-a induced activation of human monocytic cells via modulating transmembrane TNF-Ctmediated "reverse signaling". Int J Mol Med 2006; 18: 885-92.
15. Yu M, Shi W, Zhang J , et al. Influence of reverse signaling via membrane TNF-CC on cytotoxicity of NK92 cell. Eur J Cell Biol 2009; 88:181-91.
16. Salfeld J , Kaymakcalan Z, Tracey D, Robert A, Kamen R. Generation of fully human anti-TNF antibody D2E7. Arthritis Rheum 1998; 41: S57.
17. Weir N, Athwal D, Brown D, et al. A new generation of high-affinity humanized PEGylated Fab' fragment antitumor necrosis factor-(alpha) monoclonal antibodies. Therapy 2006; 3: 535-45. (Pubitemid 44420582)
18. Kohno T, Tarn L, Ting T, Bass RB, Stevens SR. Adalimumab and infliximab bind to Fc-receptor and Clq and generate immunoprecipitation: a different mechanism from etanercept. Arthritis Rheum 2005; 52 (9): S562-S563.
19. Lobo ED, Hansen RJ, Balthasar J P. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004; 93: 2645-68. (Pubitemid 39506617)
20. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008; 117 (2): 244-79.
21. Shealy D, Cai A, Staquet K, et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha. MAbs 2010; 8; 2 (4).
22. Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002; 301: 418-26. (Pubitemid 34429950)
23. Kohno T, Tarn LT, Stevens SR, Louie J S. Binding characteristics of tumor necrosis factor receptor-Fc fusion proteins vs anti-tumor necrosis factor mAbs. J Investig Dermatol Symp Proc 2007; 12: 5-8. (Pubitemid 46763031)
24. Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Injlamm Bowel Dis 2007; 13:1323-32. (Pubitemid 350206841)
25. Kaymakcalan Z, Sakorafas P, Bose S, et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 2009; 131: 308-16.
26. Ehrenstein MR, Evans J G, Singh A, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004; 200: 277-85. (Pubitemid 39031247)
27. Alessandri C, Bombardieri M, Papa N, et al. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNF alpha therapy infliximab in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 2004; 63:1218-21. (Pubitemid 39273496)
28. Chen HA, Lin KC, Chen CH, et al.The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 35-9. (Pubitemid 41815636)
29. Atzeni F, Sarzi-Puttin, P, Dell'Acqua D, et al. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a oneyear prospective study. Arthritis Res Ther 2006; 8: R3.
30. Lorenz HM, Antoni C, Valerius T, et al. In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis short term cellular and molecular effects. J Immunol 1996; 156:1646-53.
31. Maurice MM, Van Der Graaff WL, Leow A, Breedveld FC, Van Lier RAW, Verweij CL. Treatment with monoclonal anti-tumor necrosis factor a antibody results in an accumulation of Thl CD4+T cells in the peripheral blood of patients with rheumatoid arthritis. Arthritis Rheum 1999; 42: 2166-73. (Pubitemid 30263601)
32. Bryl E, Vallejo AN, Matteson EL, Witkowski J M, Weyand CM, GoronzyJJ. Modulation of CD28 expression with anti- tumor necrosis factor alpha therapy in rheumatoid arthritis. Arthritis Rheum 2005; 52: 2996-3003. (Pubitemid 41447078)
33. Mueller RB, Skapenko A, Grunke M, et al. Regulation of myeloid cell function and major histocompatibility complex class II expression by tumor necrosis factor. Arthritis Rheum 2005; 52: 451-60. (Pubitemid 40216309)
34. Barrera P, Joosten LA, den Broeder AA, van de Putte LB, van Riel PL, van den Berg WB. Effects of treatment with a fully human antitumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNF-alpha in patients with rheumatoid arthritis. Ann Rheum Dis 2001; 60: 660-9. (Pubitemid 32588369)
35. Charles P, Elliott MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999; 163:1521-8. (Pubitemid 29352775)
36. Kaymakcalan Z, Beam C, Salfeld J. Murine model for assessing adalimumab, infliximab, and etanercept to prevent polyarthritis. Ann Rheum Dis 2003; 62 (Suppl 1): 136-7.
37. Wee S, Pascual M, Eason J D, et al. Biological effects and fate of a soluble, dimeric, 80-Kda tumor necrosis factor receptor in renal transplant recipients who receive OKT3 therapy 1. Transplantation 1997; 63: 570-7. (Pubitemid 27102627)
38. Mitoma H, Horiuchi T, Tsukamoto H, et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum 2008; 58 (5): 1248-57. (Pubitemid 351705913)
39. Arora T, Padaki R, Liu L, et al. Differences in binding and effector functions between classes of TNF antagonists. Cytokine 2009; 45: 124-31.
40. Shohet J M, Pemberton P, Carroll MC. Identification of a major binding site for complement C3 on the IgGl heavy chain. J Biol Chem 1993; 268: 5866-71. (Pubitemid 23090920)
41. Sahu A, Pangburn MK. Covalent attachment of human complement C3 to IgG. Identification of the amino acid residue involved in ester linkage formation. J Biol Chem 1994; 269:28997-9002.
42. Vidarte L, Pastor C, Mas S, et al. Serine 132 is the C3 covalent attachment point on the CHI domain of human IgGl. J Biol Chem 2001; 276: 38217-23.
43. Siberil S, Dutertre C-A, Boix C, et al. Molecular aspects of human FcgR interactions with IgG: functional and therapeutic consequences. Immunol Lett 2006; 106:111-8.
44. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995; 7: 251-9.
45. Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford) 2010; 49 (7): 1215-28.
46. Plant D, Bowes J , Potter C, Hyrich KL, Morgan AW, Wilson AG, Isaacs J D; Wellcome Trust Case Control Consortium; British Society for Rheumatology Biologies Register, Barton A. Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum 2011; 63 (3): 645-53.
47. Isaacs J D, Ferraccioli G. The need for personalised medicine for rheumatoid arthritis. Ann Rheum Dis 2011; 70 (1):4-7.